Survival and Side Effects of Cisplatin/Cyclophosphamide and Carboplatin/Paclitaxel Adjuvant Chemotherapy in Stage IC-IV Ovarian Cancer

Abstract

Objective: To compare the survival and side effects in epithelial
 ovarian cancer patients receiving adjuvant chemotherapy of cisplatin/
 cyclophosphamide and carboplatin/paclitaxel.
 
 Method: We recruited epithelial ovarian cancer patients receiving
 cisplatin/cyclophosphamide (group A) or carboplatin/paclitaxel
 (group B) adjuvant chemotherapy after surgery. Chemotherapy was
 given for six cycles. Overall survival and side effects were assessed.
 
 Result: A total of 49 patients were recruited, consisting of 25 patients
 for group A and 24 patients for group B. In this study, the overall
 survival of stage IC-IV ovarian cancer patients was 37.3 months in
 group A (95%CI=31.86-43.46) and 35.5 months (95%CI= 13.93-
 43.46) in group B (p